08:54 AM EDT, 09/16/2024 (MT Newswires) -- Jazz Pharmaceuticals ( JAZZ ) said Monday that updated data from the mid-stage study of its experimental therapy, zanidatamab, combined with chemotherapy for HER2-positive advanced or metastatic gastroesophageal adenocarcinoma were positive.

Data showed that among 41 patients treated with zanidatamab in combination with chemotherapy, the median progression-free survival was 15.2 months, and the Kaplan-Meier-estimated overall survival of 59% at 30 months.

The company said the combination therapy also showed an 84% confirmed overall response rate, with a median response duration of 18.7 months.

Jazz Pharmaceuticals ( JAZZ ) said it is continuing to advance its clinical program for zanidatamab in gastroesophageal adenocarcinoma, which includes a late-stage trial that is expected to be completed in Q2 next year.

Price: 110.79, Change: +2.00, Percent Change: +1.84